Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564873 · ClinicalTrials.gov registry record · Phase 1
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
A Phase 1 study of High Grade Myelodysplastic Syndromes, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03564873 is a Phase 1 study of High Grade Myelodysplastic Syndromes that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03564873, a Phase 1 study of High Grade Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Omacetaxine
Study Locations (1)
Colorado
- Universtiy of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03564873
The ClinicalTrials.gov registry entry for NCT03564873 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT03564873 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03564873 about?
NCT03564873 is a clinical study titled "Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS". This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.
What is the current status of trial NCT03564873?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-09-17. Estimated completion is 2027-06.
What conditions does trial NCT03564873 study?
This clinical trial studies the following conditions: High Grade Myelodysplastic Syndromes.
What interventions are being tested in trial NCT03564873?
The interventions under investigation include: Azacitidine (DRUG), Omacetaxine (DRUG).
Who is sponsoring clinical trial NCT03564873?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03564873 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.